- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.11. | Upstream Bio, Inc. reports Q3 results | 2 | Seeking Alpha | ||
| 05.11. | Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress | 129 | GlobeNewswire (Europe) | - Positive top-line results from VIBRANT Phase 2 trial of verekitug in CRSwNP reported in September showed statistically significant and clinically meaningful effects on primary and key secondary... ► Artikel lesen | |
| 05.11. | Upstream Bio, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11. | Upstream Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.10. | Piper Sandler reiterates Overweight rating on Upstream Bio stock | 3 | Investing.com | ||
| 14.10. | Truist Securities initiates Upstream Bio stock with Buy rating on respiratory drug potential | 2 | Investing.com | ||
| 14.10. | Upstream Bio: Truist Securities startet Coverage mit Kaufempfehlung dank Potenzial bei Atemwegsmedikament | 1 | Investing.com Deutsch | ||
| 30.09. | Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress | 337 | GlobeNewswire (Europe) | - Data show verekitug prevents TSLP binding to the TSLP receptor by occupying ligand binding sites - - Additionally, findings show that verekitug outcompetes TSLP in the presence of preformed heterodimeric... ► Artikel lesen | |
| UPSTREAM BIO Aktie jetzt für 0€ handeln | |||||
| 09.09. | Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum | 1 | GlobeNewswire (USA) | ||
| 02.09. | Upstream Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.09. | Upstream Bio Reports Positive Top-line Results From Phase 2 VIBRANT Study | 7 | RTTNews | ||
| 26.08. | Piper Sandler reiterates Overweight rating on Upstream Bio stock | 2 | Investing.com | ||
| 06.08. | Upstream Bio, Inc. reports Q2 results | 1 | Seeking Alpha | ||
| 06.08. | Upstream Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.08. | Upstream Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 28.07. | JPMorgan reiterates Overweight rating on Upstream Bio stock ahead of trial data | 3 | Investing.com | ||
| 08.07. | Upstream Bio startet Phase-2-Studie für COPD-Medikament Verekitug | 1 | Investing.com Deutsch | ||
| 08.07. | Upstream Bio begins phase 2 COPD trial for verekitug | 1 | Investing.com | ||
| 08.07. | Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD) | 288 | GlobeNewswire (Europe) | - Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD - - Broadens global development program for... ► Artikel lesen | |
| 15.06. | Upstream Bio: Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor | 3 | GlobeNewswire (USA) |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 186,15 | 0,00 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| VERA THERAPEUTICS | 41,260 | 0,00 % | Why Vera Therapeutics Stock Rocked the Market on Tuesday | ||
| ARCUTIS BIOTHERAPEUTICS | 29,960 | 0,00 % | Mizuho raises Arcutis Biotherapeutics stock price target on strong Zoryve sales | ||
| NURIX THERAPEUTICS | 16,830 | 0,00 % | Nurix to host webcast on bexobrutideg clinical data next week | ||
| OLEMA PHARMACEUTICALS | 27,265 | 0,00 % | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| ARCELLX | 72,94 | 0,00 % | CAR-Therapy Keeps Analyst Confidence in Arcellx (ACLX) High Ahead of the ASH Meeting | ||
| ADMA BIOLOGICS | 19,700 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| DYNE THERAPEUTICS | 20,100 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights | - Topline data from Registrational Expansion Cohort of DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in DMD on track for December 2025 to support potential submission... ► Artikel lesen | |
| TREVI THERAPEUTICS | 13,705 | +2,66 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer | Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth
NEW HAVEN, Conn., Dec. 4, 2025 /PRNewswire/ -- Trevi Therapeutics... ► Artikel lesen | |
| KEROS THERAPEUTICS | 18,090 | 0,00 % | Keros Therapeutics, Inc.: Keros Therapeutics Announces Final Results of Tender Offer | LEXINGTON, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), today announced the final results of its cash tender offer (the "Tender Offer")... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 81,88 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 13,350 | 0,00 % | Hagens Berman Sobol Shapiro LLP: MoonLake Immunotherapeutics' (MLTX) Stock Crashes 90%, Triggers Lawsuit After Reported Phase 3 Trial Data for Sole Drug Candidate -- Hagens Berman | SAN FRANCISCO, Nov. 28, 2025 /PRNewswire/ -- MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology company, has been hit with a securities... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 14,670 | 0,00 % | Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 31,560 | 0,00 % | Structure Therapeutics stock holds Buy rating at H.C. Wainwright ahead of key trials | ||
| NUVATION BIO | 8,375 | 0,00 % | Nuvation Bio Shares Rise 8.4% After Positive Phase 2 Results In Grade-2 IDH1 Glioma |
UPSTREAM BIO INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 26,970 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu UPSTREAM BIO INC finden Sie auf Wallstreet Online.